[TALK 22] Biophysics in Drug Discovery: Chris Stubbs & Geoff Holdgate

Biophysics in Drug Discovery
Speakers: Chris Stubbs & Geoff Holdgate, AstraZeneca, UK
2024 Introduction to Biophysical Techniques
In this video, Geoff Holdgate gives an overview of drug discovery at AstraZeneca. He discusses why it is so difficult to make drugs and what chemical properties are optimal for drugs. He explains how biophysics fits within the drug programme operation model and what questions it can answer at different stages of the process. In the second part of the talk, Chris Stubbs describes the biophysical tools used at AstraZeneca. He details examples of how these tools have answered critical questions such as reagent quality control, hit identification and validation. He shows how different techniques can overcome an apparent potency limit highlighting their strengths and weaknesses. He lastly looks at using biophysical techniques to understand molecular glues.
Read more about AstraZeneca’s work here:
www.astrazeneca.com/r-d.html
You can find more videos from the LMB 2024 Biophysics Techniques Lecture series here:
• Biophysical Techniques...
--
About the MRC Laboratory of Molecular Biology (LMB):
The LMB is one of the world's leading research institutes. Discoveries and inventions developed at the LMB, for example DNA sequencing and methods to determine the structure of proteins, have revolutionised all areas of biology. Our scientists work to advance understanding of biological processes at the molecular level. This information will help us to understand the workings of complex systems, such as the immune system and the brain, and solve key problems in human health.
More links:
Official Site: www2.mrc-lmb.cam.ac.uk/
Facebook: / mrc.lmb
X/Twitter: / mrc_lmb
Instagram: / mrc_lmb
LinkedIn: / mrc-laboratory-of-mole...
Click here to subscribe to MRC Laboratory of Molecular Biology on KZbin: kzbin.info...

[@bamh1re318]

with the advance of biochemistry, digital/structure, and wide arrays of CRO steps from screening to pre-clinical efficacy becomes straight forward. The bottle neck seems to be the first step: target selection. Too few disease-drivers which attract huge crowd!